8-K: Profound Medical Appoints Interim CFO, Transition Plan in Place

Profound Medical Corp. announced the appointment of Matthew Sobczyk as Interim Chief Financial Officer and detailed a separation agreement with former CFO Rashed Dewan, including transition services.

Summary

• Matthew Sobczyk has been appointed as the Interim Chief Financial Officer of Profound Medical Corp., effective August 14, 2026.
• Mr. Sobczyk has been with the company since May 2017, holding various senior financial roles, most recently as Corporate Controller.
• Rashed Dewan has resigned as Chief Financial Officer, effective August 14, 2026.
• A mutual separation agreement includes a severance payment of $375,000 to Mr. Dewan, continued benefits for 15 months, and extended stock option exercisability.
• Mr. Dewan will also provide transition and advisory services as an independent contractor from August 17, 2026, to November 25, 2026, for CAD 200 per hour.
• Mr. Sobczyk's annual base salary will be CAD 300,414.58, with a target annual discretionary bonus of 15% of his base salary.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, primarily due to the internal promotion and the smooth transition plan for the departing CFO, though the change itself is a common occurrence.

Positives

• Internal promotion of Matthew Sobczyk to Interim CFO, indicating continuity and trust in existing talent.
• Mr. Sobczyk has extensive experience within Profound Medical, having served in senior financial roles since 2017.
• A clear transition plan is in place, with the former CFO providing consulting services for a defined period.
• The company is providing Mr. Dewan with a severance package, including cash, benefits continuation, and extended stock option exercise periods.

Negatives

• The departure of a Chief Financial Officer can sometimes signal underlying issues or a lack of confidence in the company's financial direction.
• The severance package and consulting fees represent an additional cost to the company.

Risks

• Potential for disruption in financial operations during the interim period, despite the transition plan.
• The company's reliance on forward-looking statements carries inherent risks, as actual results may differ materially due to market conditions, regulatory approvals, and competition.

Future Outlook

The company continues to execute its growth strategy and drive adoption of its TULSA technology, with the new Interim CFO expected to maintain continuity and operational discipline. Forward-looking statements indicate expectations regarding the efficacy of Profound's technologies and future revenues, though actual results may differ.

Management Comments

• "I would like to thank Rashed for his years of service and the contributions he has made to the Company, and I am pleased that he will be staying on a short-term consulting contract to help ensure a smooth transition."
• "At the same time, given Matthews deep knowledge of Profound, combined with his financial expertise and experience, we are confident that he is the right leader to maintain continuity and operational discipline while we continue to execute our growth strategy and drive adoption of our award-winning TULSA technology."

Industry Context

StockSavvy.ai notes that CFO transitions are common in the dynamic medical device sector, especially for commercial-stage companies focused on growth and technology adoption. Profound Medical's focus on interventional MRI (iMRI) procedures, particularly its TULSA-PRO and Sonalleve platforms, places it in a competitive landscape where financial leadership continuity is crucial for navigating regulatory approvals, market penetration, and investor relations.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of an experienced interim CFO and a clear transition plan are intended to maintain stability and confidence.
• Employees: The change in CFO may lead to adjustments in financial reporting and operational focus, but continuity is emphasized.
• Creditors: The company's ongoing operations and financial management are expected to continue without significant disruption.

Next Steps

• Matthew Sobczyk to serve as Interim Chief Financial Officer, ensuring continuity.
• Rashed Dewan to provide transition and advisory services as an independent contractor until November 25, 2026.
• Company to continue executing its growth strategy and driving adoption of TULSA technology.

Key Dates

Recommendation

The filing reports a routine management change (CFO transition) with a well-structured plan for continuity. While the departure of a CFO can be a point of concern, the internal promotion and the former CFO's continued advisory role suggest a stable handover. The company's core business and technology remain the primary drivers, and this event alone does not warrant a significant shift in investment strategy, thus a 'hold' recommendation is appropriate pending further operational or financial updates.

Keywords

Interim Chief Financial Officer, Management Change, CFO Resignation, Separation Agreement, Consulting Services, Medical Device Company, Profound Medical Corp.